Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SoftInhaler is a German medical technology company specializing in the development of high-performance pulmonary drug delivery devices. The company's flagship technology is a proprietary Soft Mist Inhaler (SMI) platform that generates a slow-moving, long-lasting aerosol cloud to maximize deep lung deposition. This breath-triggered system is designed to overcome the coordination challenges associated with traditional inhalers, thereby improving dose consistency and patient adherence. SoftInhaler collaborates with pharmaceutical and biotechnology firms to adapt its platform for a wide range of therapeutics, including small molecules and biologics for both local respiratory and systemic applications. Led by world-renowned aerosol expert Dr. Gerhard Scheuch, the company provides end-to-end expertise in aerosol science, device engineering, and clinical trial support for inhaled therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Soft-Inhaler.